INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 25 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,197,000 | +15.5% | 1,601,000 | 0.0% | 0.00% | – |
| Q2 2022 | $1,036,000 | -61.3% | 1,601,000 | -63.8% | 0.00% | – |
| Q1 2022 | $2,674,000 | +5.1% | 4,426,000 | 0.0% | 0.00% | – |
| Q4 2021 | $2,545,000 | -53.4% | 4,426,000 | -52.7% | 0.00% | -100.0% |
| Q3 2021 | $5,460,000 | -12.8% | 9,351,000 | -0.3% | 0.00% | 0.0% |
| Q2 2021 | $6,259,000 | +2.1% | 9,383,000 | -0.8% | 0.00% | 0.0% |
| Q1 2021 | $6,132,000 | +49.6% | 9,455,000 | +33.1% | 0.00% | 0.0% |
| Q4 2020 | $4,098,000 | -29.2% | 7,105,000 | -14.7% | 0.00% | 0.0% |
| Q3 2020 | $5,790,000 | +52.8% | 8,329,000 | +58.7% | 0.00% | 0.0% |
| Q2 2020 | $3,789,000 | +161.5% | 5,248,000 | +218.1% | 0.00% | – |
| Q1 2020 | $1,449,000 | -65.6% | 1,650,000 | -48.2% | 0.00% | -100.0% |
| Q4 2019 | $4,210,000 | +178.1% | 3,186,000 | +90.2% | 0.00% | – |
| Q3 2019 | $1,514,000 | +52.6% | 1,675,000 | +67.5% | 0.00% | – |
| Q2 2019 | $992,000 | – | 1,000,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $39,071,000 | 2.11% |
| PenderFund Capital Management Ltd. | 5,000,000 | $4,719,000 | 1.31% |
| Opti Capital Management, LP | 13,246,000 | $9,340,000 | 1.14% |
| Context Partners Fund, L.P. | 7,485,000 | $5,145,000 | 1.12% |
| Context Capital Management, LLC | 7,485,000 | $5,145,000 | 1.12% |
| Soros Fund Management | 19,552,000 | $13,548,000 | 0.33% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 18,604,000 | $12,963,000 | 0.29% |
| Senvest Management, LLC | 5,000,000 | $3,465,000 | 0.20% |
| CSS LLC/IL | 2,825,000 | $1,957,000 | 0.09% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 350,000 | $243,000 | 0.04% |